IAP12 Rec'd PCT/PTO 06 DEC 2005

What claims is:

10

15

20

1. (original) A compound of the general formula I:

$$\mathbb{R}^4$$
 \mathbb{R}^5
 \mathbb{R}^1
 \mathbb{R}^2
 \mathbb{R}^2

wherein R^1 is H; $C_1 \sim C_4$ branched or straight chain alkyl; $C_1 \sim C_4$ halogenated branched or straight chain alkyl; $C_2 \sim C_6$ alkenyl; $C_2 \sim C_4$ alkynyl; pyridyl, pyrimidinyl, imidazolyl; except H, the above substituents may be optionally substituted with one or more following groups: halogen, cyano, nitro, hydroxyl, carboxyl, guanidino, $C_1 \sim C_4$ alkyl, $C_1 \sim C_4$ alkoxyl, $C_1 \sim C_4$ alkanoyl, $C_3 \sim C_5$ cycloalkyl, substituted phenyl, substituted heterocyclic group, $CONR^5R^6$, NR^5R^6 , CO_2R^7 , $NHSO_2R^8$ or $SO_2NR^9R^{10}$;

 R^2 is H; $C_1 \sim C_3$ branched or straight chain alkyl; $C_1 \sim C_3$ halogenated branched or straight chain alkyl; $C_2 \sim C_6$ alkenyl; $C_2 \sim C_4$ alkynyl; substituted phenyl; except H, the above substituents may be optionally substituted with one or more following groups: halogen, cyano-, nitro, hydroxyl, carboxyl, guanidino-, $C_1 \sim C_4$ alkyl, $C_1 \sim C_4$ alkoxyl, $C_1 \sim C_4$ alkanoyl, $C_3 \sim C_5$ cycloalkyl, substituted heterocyclic group, $CONR^6R^7$, NR^6R^7 , CO_2R^8 , $NHSO_2R^9$ or $SO_2NR^{10}R^{11}$;

 R^3 is H; $C_1 \sim C_6$ branched or straight chain alkyl which may be optionally substituted with $C_3 \sim C_6$ cycloalkyl or $C_1 \sim C_4$ alkoxyl; $C_2 \sim C_4$ alkenyl; $C_2 \sim C_4$ alkynyl;

 R^4 is H; C_1 - C_6 branched or straight chain alkyl which may be optionally substituted with C_3 - C_6 cycloalkyl or C_1 - C_4 alkoxyl; C_2 - C_4 alkenyl; C_2 - C_4 alkynyl;

 \mbox{R}^{5} is H; $\mbox{C}_{1}{\sim}\mbox{C}_{4}$ branched or straight chain alkyl which may be optionally

---, ------, ----,

substituted with OH, NR^6R^7 , CN, $CONR^6R^7$ or CO_2R^8 ; $C_2\sim C_4$ alkenyl which may be optionally substituted with CN, $CONR^6R^7$ or CO_2R^8 ; $C_2\sim C_4$ alkoxyl optionally substituted with NR^6R^7 ; $(C_2\sim C_3$ alkoxyl) $C_1\sim C_2$ branched or straight chain alkyl optionally substituted with OH or NR^6R^7 ; $CONR^6R^7$; CO_2R^8 ; halogen; NR^6R^7 ; $NHSO_2NR^6R^7$; $NHSO_2R^9$; $SO_2NR^{10}R^{11}$; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl, or triazolyl, either of which is optionally substituted with methyl;

 R^6 and R^7 are each independently H or $C_1 \sim C_4$ branched or straight chain alkyl; or R^6 and R^7 together with their attached nitrogen atom form pyrrolinyl, piperidyl, morpholinyl, $4-N(R^{12})$ -piperazinyl or imidazolyl, either of which is optionally substituted with methyl or hydroxyl;

 R^8 is H; $C_1 \sim C_6$ branched or straight chain alkyl optionally substituted with $C_1 \sim C_4$ alkoxyl, $C_1 \sim C_4$ alkylamino, dialkylamino; substituted phenyl and substituted heterocyclic group in which the substitut(s) on the ring of substituted phenyl and substituted heterocyclic group are defined as the above;

 R^9 is C_1-C_3 alkyl optionally substituted with NR^6R^7 ;

10

15

20

25

 \mbox{R}^{10} and \mbox{R}^{11} are each independently H or $C_1{\sim}C_{12}$ branched or straight chain alkyl; $C_1 \sim C_3$ halogenated branched or straight chain alkyl; $C_2 \sim C_6$ alkenyl; $\text{C}_2\text{~C}_6$ alkynyl or $\text{C}_3\text{~C}_6$ cycloalkyl; or R^{10} and R^{11} take together to form a pyrrolinyl, pyrrolinone group, piperidyl, morpholinyl, $4-N(R^{13})$ -piperazinyl; or R^{10} and R^{11} together with their attached nitrogen atom form a pyrrolinyl, pyrrolinone group, piperidyl, morpholinyl, $4-N(R^{13})$ -piperazinyl which are optionally substituted with OH, CN, CO_2R^8 , $C_1 \sim C_4$ branched or straight chain alkyl, $C_1 \sim C_3$ alkoxyl, $NR^{14}R^{15}$ or $CONR^{14}R^{15}$; substituted phenyl, substituted heterocyclic group, or $C_1\text{-}C_6$ branched or straight chain alkyl substituted with substituted phenyl or substituted heterocyclic group, the said groups are optionally further substituted with OH, CO_2R^8 , $NR^{14}R^{15}$, $CONR^{14}R^{15}$, or linked together with

another substituted phenyl or substituted heterocyclic group by a carbonyl group;

5

10

15

20

25

 R^{12} is H; $C_1 \sim C_6$ branched or straight chain alkyl which may be optionally substituted with phenyl, $C_2 \sim C_3$ alkyl substituted by hydroxyl, or $C_1 \sim C_4$ alkoxyl; $C_1 \sim C_3$ fluoroalkyl; $C_2 \sim C_6$ alkenyl; $C_2 \sim C_6$ alkynyl; or $C_3 \sim C_6$ cycloalkyl; R^{13} is H; $C_1 \sim C_6$ branched or straight chain alkyl; $C_2 \sim C_6$ branched or straight chain alkyl substituted with $C_1 \sim C_3$ alkoxyl; $C_2 \sim C_6$ branched or straight chain alkyl substituted with hydroxyl; $C_2 \sim C_6$ branched or straight chain alkyl substituted with $NR^{14}R^{15}$; $C_2 \sim C_6$ branched or straight chain alkyl substituted with phenyl; $C_1 \sim C_6$ branched or straight chain alkyl substituted with $CONR^{14}R^{15}$; $C_2 \sim C_6$ branched or straight chain hydrocarbyl substituted with CO_2R^8 ; $C_2 \sim C_6$ branched or straight chain hydrocarbyl having substituted phenyl or substituted heterocyclic group as substituent; CO_2R^8 , $CONR^{14}R^{15}$, $CSNR^{14}R^{15}$ or $C(NH)NR^{14}R^{15}$; $C_1 \sim C_3$ halogenated branched or straight chain alkyl; $C_2 \sim C_6$ alkenyl; $C_2 \sim C_6$ alkynyl or $C_3 \sim C_6$ cylcloalkyl; or polyethylene glycol group $(n=2 \sim 20)$, which is optionally substituted with $C_1 \sim C_6$ alkyl on its terminal;

 R^{14} and R^{15} are each independently H; $C_1 \sim C_4$ branched or straight chain alkyl; $C_2 \sim C_4$ branched or straight chain alkyl substituted with $C_1 \sim C_3$ alkoxyl; or $C_2 \sim C_4$ branched or straight chain alkyl substituted with hydroxyl; or R^{14} and R^{15} together with their attached nitrogen atom form a pyrrolinyl, pyrrolinone group, piperidyl or morpholinyl; and

the substituted phenyl refers to a phenyl which is substituted with one or more groups selected from $C_1 \sim C_4$ alkoxyl, halogen, cyano-, CF_3 , OCF_3 , $C_1 \sim C_4$ branched or straight chain alkyl on the phenyl ring; The substituted heterocyclic group refers to hexatomic rings containing one or two nitrogen atoms , and the oxides thereof; pentatomic rings containing two or three hetero-atom selected a group consisted of nitrogen, oxygen, and sulfur atoms; the substituting groups on the heterocyclic ring are

 $C_1 \sim C_4$ branched or straight chain alkyl, $C_1 \sim C_4$ alkoxyl, amino, as well as $C_1 \sim C_4$ branched or straight chain alkyl amino, $C_1 \sim C_4$ alkoxylamino group; Or their pharmaceutically acceptable salts .

- 2. (original) The compound according to claim 1, wherein: R^1 is $C_1 \sim C_3$ branched or straight chain alkyl optionally substituted with one or more groups selected from a group consisted of the following: $C_1 \sim C_4$ alkyl, $C_1 \sim C_4$ alkoxyl, $C_1 \sim C_4$ alkanoyl, substituted phenyl, substituted heterocyclic group, $CONR^6R^7$ and NR^6R^7 ;
- R² is H; C₁~C₃ branched or straight chain alkyl optionally substituted with one or more groups selected from a group consisted of the following: substituted phenyl, substituted heterocyclic group, CONR⁶R⁷, and NR⁶R⁷;

 R³ is H; C₂~C₄ branched or straight chain alkyl which may be optionally substituted with C₃~C₄ cycloalkyl, C₁~C₃ alkoxyl; C₂~C₄ alkenyl; or C₂~C₄ alkynyl;

 R^4 is H; $C_1\sim C_4$ branched or straight chain alkyl which may be optionally substituted with $C_3\sim C_5$ cycloalkyl or $C_1\sim C_3$ alkoxyl; $C_2\sim C_4$ alkenyl; or $C_2\sim C_4$ alkynyl;

 R^5 is H; $C_1 \sim C_4$ branched or straight chain alkyl which may be optionally substituted with OH, NR^6R^7 , CN, $CONR^6R^7$ or CO_2R^6 ; $C_2 \sim C_4$ alkoxyl optionally substituted with NR^6R^7 ; NR^6R^7 ; $NHSO_2NR^6R^7$; $NHSO_2R^9$; $SO_2NR^{10}R^{11}$; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl, either of which is optionally substituted with methyl;

20

25

 R^6 and R^7 are each independently H; $C_1 \sim C_4$ branched or straight chain alkyl, or R^6 and R^7 together with their attached nitrogen atom form a pyrrolinyl, piperidyl, morpholinyl, $4-N(R^{12})$ -piperazinyl or imidazolyl, either of which is optionally substituted with methyl and hydroxyl;

 R^8 is H or $C_1 \sim C_4$ branched or straight chain alkyl;

 R^9 is $C_1 \sim C_3$ alkyl optionally substituted with NR^6R^7 ;

10

15

 \mbox{R}^{10} and \mbox{R}^{11} are each independently H or $\mbox{C}_{1}{\sim}\mbox{C}_{12}$ branched or straight chain alkyl; $C_1 \sim C_3$ halogenated branched or straight chain alkyl; $C_2 \sim C_6$ alkenyl; $C_2 \sim C_6$ alkynyl or $C_3 \sim C_6$ cylcoalkyl; or R^{10} and R^{11} taken together to form pyrrolinone pyrrolinyl, group, piperidyl, morpholinyl, $4-N(R^{13})$ -piperazinyl; or R^{10} and R^{11} together with their attached nitrogen atom form a pyrrolinyl, pyrrolidone group, piperidyl, morpholinyl, $4-N(R^{13})$ -piperazinyl; the said groups are optionally substituted with OH, CN, CO_2R^8 , $C_1\sim C_4$ branched or straight chain alkyl, $C_1\sim C_3$ alkoxyl, $NR^{14}R^{15}$, or $\text{CONR}^{14}\text{R}^{15}$; substituted phenyl, substituted heterocyclic group, or $\text{C}_1{\sim}\text{C}_6$ branched or straight alkyl substituted with substituted phenyl or substituted heterocyclic group, the said groups are further substituted with OH, CO_2R^8 , $\text{NR}^{14}\text{R}^{15}$, $\text{CONR}^{14}\text{R}^{15}$, or linked together with another substituted phenyl or substituted heterocyclic group by a carbonyl group;

 R^{12} is H; $C_1 \sim C_6$ branched or straight chain alkyl which may be optionally substituted with $C_2 \sim C_3$ alkyl or $C_1 \sim C_4$ alkoxyl, the said alkyl and alkoxyl are substituted with phenyl, hydroxyl; $C_2 \sim C_6$ alkenyl or $C_3 \sim C_6$ cylcoalkyl;

20 R¹³ is H; C₁~C₆ branched or straight chain alkyl; C₂~C₆ branched or straight chain alkyl substituted with C₁~C₃ alkoxyl; C₂~C₆ branched or straight chain alkyl substituted with hydroxyl; C₂~C₆ branched or straight chain alkyl substituted with NR¹⁴R¹⁵; C₂~C₃ branched or straight chain alkyl substituted with phenyl; C₁~C₆ branched or straight chain alkyl substituted with phenyl; C₁~C₆ branched or straight chain alkyl substituted with CONR¹⁴R¹⁵; CO₂R⁸, CONR¹⁴R¹⁵, CSNR¹⁴R¹⁵ or C(NH)NR¹⁴R¹⁵; C₁~C₃ halogenated branched or straight chain alkyl; C₂~C₆ alkenyl; C₂~C₆ alkynyl or C₃~C₆ cylcoalkyl;

 R^{14} and R^{15} are each independently H; $C_1{\sim}C_4$ branched or straight chain alkyl; $C_2{\sim}C_4$ branched or straight chain alkyl substituted with $C_1{\sim}C_3$

alkoxyl; or $C_2 \sim C_4$ branched or straight chain alkyl substituted with hydroxyl; or R^{14} and R^{15} together with their attached nitrogen atom form pyrrolinyl, pyrrolinone group, piperidyl, or morpholinyl;

The substituted phenyl refers to a phenyl group which is substituted with one or more groups selected from $C_1 \sim C_4$ alkoxyl, halogen, CN, CF_3 , OCF_3 , or $C_1 \sim C_4$ branched or straight chain alkyl; the substituted heterocyclic group refers to hexatomic rings containing one or two nitrogen atoms, and the oxide thereof; or pentatomic rings containing two or three hetero-atom selected a group consisted of nitrogen, oxygen and sulfur atoms; the substituents on the heterocyclic ring are $C_1 \sim C_4$ branched or straight chain alkyl, $C_1 \sim C_4$ alkoxyl, amino, as well as $C_1 \sim C_4$ branched or straight chain alkyl amino, $C_1 \sim C_4$ alkoxylamino.

3. (currently amended) The compound according to claim 1-or-2, wherein

 R^1 is $C_2 \sim C_3$ branched or straight chain alkyl which may be optionally substituted with one or more groups selected from substituted heterocyclic group and NR^6R^7 ;

R² is H;

5

10

15

 R^3 is H; $C_2 \sim C_4$ branched or straight chain alkyl which may be optionally substituted with $C_3 \sim C_4$ cycloalkyl; $C_2 \sim C_4$ alkenyl; $C_2 \sim C_4$ alkynyl;

20 R^4 is $C_2\sim C_4$ branched or straight chain alkyl, which may be optionally substituted with $C_1\sim C_3$ alkoxyl; $C_2\sim C_4$ alkenyl; $C_2\sim C_4$ alkynyl;

 R^5 is $SO_2NR^{10}R^{11}$;

R⁶ and R⁷ together with their attached nitrogen atom form a pyrrolinyl, piperidyl or morpholinyl;

25 R^8 is H or $C_1 \sim C_4$ branched or straight chain alkyl;

 R^{10} and R^{11} are each independently H or $C_1 \sim C_{12}$ branched or straight chain alkyl; $C_3 \sim C_6$ cylcoalkyl; or R^{10} and R^{11} take together to form a pyrrolinyl,

pyrrolinone group, piperidyl, morpholinyl, $4-N(R^{13})$ -piperazinyl; or R^{10} and R^{11} together with their attached nitrogen atom form a pyrrolinyl, pyrrolinone group, piperidyl, morpholinyl, or $4-N(R^{13})$ -piperazinyl; the said groups are optionally substituted with OH, $C_1\sim C_4$ branched or straight chain alkyl, $C_1\sim C_3$ alkoxyl, $NR^{14}R^{15}$, or $CONR^{14}R^{15}$; substituted phenyl, substituted heterocyclic group, or $C_1\sim C_6$ branched or straight alkyl optionally substituted with substituted phenyl, substituted heterocyclic group, the said groups are further substituted with OH, CO_2R^8 , $NR^{14}R^{15}$ or $CONR^{13}R^{14}$, or linked together with another substituted phenyl or substituted heterocyclic group by a carbonyl;

 R^{13} is H; $C_1 \sim C_3$ branched or straight chain alkyl; $C_2 \sim C_3$ branched or straight chain alkyl substituted with $C_1 \sim C_3$ alkoxyl; $C_2 \sim C_3$ branched or straight chain alkyl substituted with OH; $C_2 \sim C_6$ branched or straight chain alkyl substituted with $NR^{14}R^{15}$; $C_2 \sim C_3$ branched or straight chain alkyl substituted with phenyl; $C_1 \sim C_6$ branched or straight chain alkyl substituted with $C_1 \sim C_6$ branched or straight chain alkyl substituted with $C_1 \sim C_6$ branched or straight chain alkyl substituted with $C_1 \sim C_6$ branched or $C_1 \sim C_6$ branched or straight chain alkyl substituted with $C_1 \sim C_6$ branched or $C_1 \sim C_6$ branched o

10

15

20

25

 R^{14} and R^{15} are each independently H; $C_1 \sim C_4$ branched or straight chain alkyl; $C_2 \sim C_4$ branched or straight chain alkyl substituted with $C_1 \sim C_3$ alkoxyl; or $C_2 \sim C_4$ branched or straight chain alkyl substituted with OH; or R^{14} and R^{15} together with their attached nitrogen atom form a pyrrolinyl, pyrrolinone group, piperidyl or morpholinyl;

the substituted phenyl refers to a phenyl group which is substituted with one or more substituents selected from a group consisted of $C_1 \sim C_4$ alkoxyl, halogen, CN, CF₃, OCF₃, and $C_1 \sim C_4$ branched or straight chain alkyl; the substituted heterocyclic group refers to hexatomic rings containing one or two nitrogen atoms and the oxide thereof; or pentatomic rings containing two or three hetero-atom selected a group consisted of nitrogen, oxygen, and sulfur atoms; the substituents on the heterocyclic ring are $C_1 \sim C_4$ branched or straight chain alkyl, $C_1 \sim C_4$

alkoxyl, amino, as well as $C_1 \sim C_4$ branched or straight chain alkyl amino, $C_1 \sim C_4$ alkoxylamino.

- 4. (currently amended) The compound according to claim [1-]3, wherein the compound is selected from a group consisting of:
- 5 2-[2-ethoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
 monohydrochloride, dihydrochloride and other possible hydrochloride
 thereof;
- 2-[2-methoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n
 10 -propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, and the hydrochloride thereof;
 - 2-[2-n-propoxy-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, and the hydrochloride thereof;
- 2-[2-allyloxy-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n
 -propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, and the
 monohydrochloride, dihydrochloride and other possible hydrochloride
 thereof;
- 2-[2-n-propoxy-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-ethyl-7-n
 20 -propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
 monohydrochloride, dihydrochloride and other possible hydrochloride
 thereof;
 - $2-[2-ethoxyl-5-(4-methylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n \\ -propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, \\ the$
- 25 monohydrochloride, dihydrochloride and other possible hydrochloride thereof;
 - 2-[2-ethoxyl-5-(4-methylpiperazinyl-1-sulfonyl)phenyl]-5-ethyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the

monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(4-ethoxycarbonylpiperazinyl-1-sulfonyl)phenyl]-5methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

5

10

25

2-[2-ethoxyl-5-(4-(2-hydroxyethyl)piperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(pyrrolidinyl-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-{2-ethoxyl-5-[3-(2-oxy-pyrrolidin-1-yl)-n-propylamino-N-sulfonyl]phenyl}-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-{2-ethoxyl-5-[2-(pyrrolidin-1-yl)-ethylamino-N-sulfonyl]phenyl}-5
20 -methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(morpholino-4-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride,dihydrochloride and other possible hydrochloride thereof;

 $2-[2-ethoxyl-5-(3-(morpholin-4-yl)-n-propylamino-N-sulfonyl) \\ phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible$

hydrochloride thereof;

5

25

2-[2-ethoxyl-5-(2-(morpholin-4-yl)-ethylamino-N-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(2,6-dimethylmorpholino-N-sulfonyl)phenyl]-5methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(1-benzylpiperidyl-4-aminosulfonyl)phenyl]-5methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(2-(piperidin-1-yl)ethylamino-1-sulfonyl)phenyl]-515 methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(4-benzylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n
-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
20 monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(4-phenylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n
-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(piperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride

. . . , ,

thereof;

5

20

25

2-[2-ethoxyl-5-(4-benzo[1,3]dioxol-5-yl-methylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d] pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-{2-ethoxyl-5-[4-(3-phenyl-n-propan-1-yl)piperidyl-1-sulfonyl] phenyl-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(n-propylamino-1-sulfonyl)phenyl]-5-methyl-7-npropyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one,the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-[2-ethoxyl-5-(N,N-di(2-hydroxyethyl)aminosulfonyl)phenyl]-5
15 methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-{2-ethoxyl-5-[N-(2-hydroxyethyl)-N-methyl]aminosulfonyl}phenyl}-5
-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-{2-ethoxyl-5-[N-(2-hydroxyethyl)-N-ethyl]aminosulfonyl}phenyl}-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-{2-ethoxyl-5-[N-(2-hydroxyethyl)-N-n-butyl]aminosulfonyl}phenyl}-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride

thereof;

5

20

25

2-{2-ethoxyl-5-(p-ethoxylcarboxylphenylamino)-N-sulfonyl}phenyl}-5methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride, dihydrochloride and other possible hydrochloride
thereof;

2-{2-ethoxyl-5-(o-benzoylphenylamino)-N-sulfonyl}phenyl}-5-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

10 2-{2-ethoxyl-5-(N2-acethydrazido)-N1-sulfonyl}phenyl}-5-methyl-7n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the
monohydrochloride and dihydrochloride and other possible hydrochloride
thereof;

2-{2-ethoxyl-5-(2-dimethylaminoethylamino)-N-sulfonyl}phenyl}-5
15 methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-ethyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof;

2-[2-ethoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5morpholinomethyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4one, the monohydrochloride, dihydrochloride and other possible
hydrochloride thereof;

2-[2-ethoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-(pyrimidiny 1-2)-methyl-7-n-propyl-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride

thereof; and

5

2-[2-ethoxyl-5-(4-ethylpiperazinyl-1-sulfonyl)phenyl]-5-methyl-7ally1-3,7-dihydropyrrolo[2,3-d]pyrimidin-4-one, the monohydrochloride, dihydrochloride and other possible hydrochloride thereof.

5. (original) A process for preparing the compounds of general formula I according to claim 1, comprising:

compound IE is reacted with compound IF:

$$R^4$$
 CI
 H_2N
 NC
 R^3
 R^3
 IE
 IF

10

in an inert solvent in the presence of an organic base as a catalyst as well as acid neutralizer at -20°C to 80°C, wherein R^1 , R^2 , R^3 , R^4 and ${\ensuremath{\mathsf{R}}}^{\ensuremath{\mathsf{5}}}$ are defined as claim 1, to obtain compound ID:

15 ID

wherein R^1 , R^2 , R^3 , R^4 and R^5 are defined as the above, then compound IA may be prepared by heating compound ID in an acidic aqueous solution:

$$\begin{array}{c|c}
R^4 & O & R^1 \\
\hline
 & N & R^3
\end{array}$$

ΙA

wherein R^1 , R^2 , R^3 , R^4 and R^5 are defined as the above,

and then a cyclization reaction of compound IA is carried out by heating and refluxing in an appropriate solution under acidic, basic or neutral condition to obtain compound of formula I:

$$\mathbb{R}^4$$
 \mathbb{R}^5
 \mathbb{R}^1
 \mathbb{R}^2
 \mathbb{R}^2

I

wherein R^1 , R^2 , R^3 , R^4 and R^5 are defined as the above;

10 or,

compound of formula I is obtained directly by cyclization of the corresponding compound ID under conditions as follows:

- a) heating to $100~300\,^{\circ}$ C in mixture of phosphorus pentoxide, water and tertiary amine, or,
- b) reacting at room temperature or reacting by heating in basic hydrogen peroxide aqueous solution, or,
 - c) reacting at room temperature or reacting by heating under acidic hydrous or anhydrous condition;

or,

5

specific example of compounds of general formula I wherein R^5 is $SO_2NR^{11}R^{12}$ may be prepared by processes as follows:

compound IC is obtained by reaction between compound IF and compound IE wherein R^5 is H;

$$\begin{array}{c|c}
R^4 & HN & R^1 \\
\downarrow & & & \\
N & & & \\
R^3 & & & \\
\end{array}$$

IC

wherein R^1 , R^2 , R^3 and R^4 are defined as the above,

then compound IB is obtained by reacting compound IC with chlorosulfonic
acid alone or in dichloromethane, chloroform, and other inert or polar
non-proton solvents,

ΙB

wherein R^1 , R^2 , R^3 and R^4 are as previously defined,

and then acylation reaction occurs between compound IB and proper amines in dichloromethane, chloroform, tertiary amine or other inert or polar non-proton solvents at $-78\,^{\circ}\mathrm{C}$ to $100\,^{\circ}\mathrm{C}$ to obtain compound of formula I wherein R^5 is $SO_2NR^{11}R^{12}$, wherein R^{11} and $R1^2$ are defined as claim 1;

or,

compound IG

5

15

 R^3-X IH

wherein R¹, R², R³, R⁴ and R⁵ are defined as claim 1, reacts with compound IH in the solvents of polar non-proton solvents in the presence of the base as catalyst to obtain compound of formula I, wherein X represents Cl, Br or I, R³ is defined as claim 1;

Optionally, compounds of the formula I can be converted into the corresponding salts by reacting with pharmaceutically acceptable acids.

- 6. (currently amended) A pharmaceutical composition containing the compound according to any one of claim[s] 1[-7] as active ingredient, and pharmaceutically acceptable excipient.
 - 7. (currently amended) A veterinary drugs composition containing the compound according to any one of claim[s] 1[-7] as active ingredient, and veterinarily acceptable excipient.
 - 8. (currently amended) Use of compounds according to any one of claim[s] [1-]7 for the manufacture of a medicament for treatment or prevention of the diseases related with phospholipase and the function thereof.
- 9. (currently amended) The use according to claim #1.8 wherein the diseases includes: male 20 sexual (erectile) dysfunction, female sexual dysfunction, premature delivery, dysmenorrhea, benign prostatic hyperlasia, bladder obstruction, incontinence, stable or unstable angina, hypertension, pulmonary hypertension, congestive heart failure, arteriosclerosis, stroke, peripheral circulatory disease, low vascular patency, chronic

asthma, allergic asthma, bronchitis, allergic rhinitis, glaucoma, disorder of the gastrointestinal movement, forerunner of the seizure, Kawasaki disease, tolerance of nitric acid ester, multiple sclerosis, peripheral nerve syndrome caused by diabetes, Alzheimer disease (AD), acute respiratory system failure, psoriasis, skin gangrene, metastasis of cancer cell, loss of hair, nutcracker esophagus, anal fissure, and hypoxia-induced vasoconstriction.

10. (original) Intermediates IA-IG for the manufacture of compound of formula I according to claims 1:

10